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With the uptake of serum treatment for diphtheria from the end
of the 19th century onwards, deaths from the disease fell
dramatically (Russell 1943), albeit, less dramatically in
countries, such as the UK, in which serum treatment had not
been adopted wholeheartedly (Weindling 1992 p 73). The
development of serum therapy of humans – in a race between
the Berlin Institute for Infectious Diseases and Emile Roux and
his colleagues at the Pasteur Institute in Paris - led to the award
of the first ever Nobel Prize in physiology or medicine, in 1901,
to Emil Behring. This illustrated that there was wide acceptance
that anti-diphtheritic serum was effective.
The accepted account of the serum’s mechanism of action was that anti-toxins produced by
artificially infected animals neutralised toxins released by diphtheria bacteria in infected humans
(measured using a method developed by Ehrlich to measure anti-toxin levels in serum).
Acceptance of the theory had been reflected in the establishment of ‘healing-serum’ factories all
over the western world, using horses (because they are large animals) as ‘anti-toxin producers’.
This orthodox explanation of the mechanism of action was challenged by the results of further
clinical trials done by Adolf Bingel, a senior physician at the district general hospital of
Brunswick, Germany (Bingel 1918). During a severe epidemic of diphtheria during the winter of
1910-1911, Bingel had become sceptical of the orthodox view that these specific ‘healing-sera’
were responsible for serum’s anti-diphtheritic effects (Bingel 1918, p 284-285): variable
responses to the anti-toxin serum had prompted him to wonder whether its beneficial effect was
due solely to the anti-toxin. Might it not be caused by a non-specific action resulting simply from
administering to patients a serum from another species? Bingel was aware of “the enormous
influences of [foreign] protein from strange [non-human] species”, as manifested in serum-
disease, and its marked effects on haematological indices. He was at pains to emphasise that he
had not the slightest intention of casting doubts on the results of animal research on immunity, but
noted that the variable clinical picture of human diphtheria, “with its numerous and diverse
complications”, was completely different from the “experimentally induced infection or intoxication
of an animal,” so “whether a drug influences a human disease can only be decided in man.” This
reasoning of species-specific pathophysiology and therapy were the basis for Bingel’s decision to
undertake a study comparing (Behring’s) ‘anti-toxin serum’ with ‘normal serum’, that is, serum
derived from horses that had not been infected with diphtheria: “If no differences are found, the
anti-toxin cannot be the effective agent” (Bingel 1918, p 284-285).
Given the widely acknowledged effectiveness of Behring’s anti-toxin serum, Bingel proceeded
cautiously, using alternation to create comparable groups of patients:
After I had treated some adult diphtheria patients with ordinary horse
serum in 1911, I began in 1912 to treat alternate adult patients with
antitoxin serum and with ordinary serum, exactly in the temporal
sequence in which they were admitted to the ward. The children all
received antitoxin serum. In the second half of the year 1912 and in the
first half of 1913, I gradually lowered the age of those to be treated with
ordinary horse serum, and from 1 July 1913 [till 31st December 1916
when he stopped the study], every second case was treated with
ordinary horse serum, whether child or adult, regardless of the severity
of the illness or the presence of complications.
Bingel noted that:
…it is absolutely inadmissible to compare the results for different time
periods, for example to give antitoxin serum during one year, and then to
give only ordinary horse serum during a second year, and then to
compare the results. That would lead to seriously wrong conclusions, for
in no infectious disease is the nature of the epidemic so changeable as
in diphtheria. Mostly we see light epidemics, but quite serious ones still
occur. I remind [the reader] of the heavy epidemics in Berlin and
Hamburg of the year 1910, and the one in Leipzig of 1914, which recall
the bad times of the period before serum. ( Bingel 1918 , p 285-286).
In addition to using alternation to address this problem, Bingel also took steps to reduce observer
biases. He noted that it was “extraordinary difficult…to evaluate the influences of therapy on
disease unless they are obvious, as for example, the success of a surgical operation or cure of
syphilis with mercury or Salvarsan. The therapeutic optimist very easily sees improvement, and
the sceptic sees nothing.” In order to reduce these problems, Bingel concealed the identity of the
two sera from his assistants and nurses, using the ‘cover names’ of ‘old serum’ (for the antitoxin
serum) and ’new serum’ or ‘red serum’ (for normal serum).
To make the trial as objective as possible, I have not relied on my own
judgment alone, but have sought the views of the assistant physicians of
the diphtheria ward, without informing them about the nature of the serum
under test (namely the ordinary horse serum). Their judgement was thus
completely without prejudice. I am keen to see my observations checked
independently, and most warmly recommend this "blind" method for the
purpose. Even the chief physician may try to draw conclusions about the
nature of the serum (unknown to him) that has been used in a particular
case: he will be astonished to see how little he is able to do
this.......Neither I nor my assistants Dr Reusz, Dr Schwab, Dr Weber, Dr
Lube could detect a difference between the two sera. Dr Koennecke
thought the old (antitoxin) serum had a certain advantage, while Dr
Rehder declared that if he were to fall ill, he would wish to be treated
with the new (horse) serum. The views of these two gentlemen thus
neutralised each other ( Bingel 1918 , p 288).
Although Bingel did not mention ‘blinding’ of the patients participating in his study, it is clear from
the context that it was a blinded trial in which patients, caregivers, and observers were blinded to
the intervention, and he recommended that others should use blinding in replications of his study
(Bingel 1918, p 288).
Bingel insisted on using measurable criteria “in order to achieve an objective overall
assessment”, which he contrasted with “impressions” from the bedside.  His final report was
based on an analysis of 471 patients treated with anti-toxin serum and 466 with normal serum
(Bingel 1918, p 309). The results were meticulously analysed and presented in detailed tables, as
well as in diagrams and illustrative case-reports. No marked differences were detected between
the impact of the two sera on the time to shedding of the diphtheritic membranes, or on mortality:
there were 47 deaths out of 471 patients (10.0 per cent) given anti-toxin serum, compared with 49
deaths out of 466 patients (10.5 per cent) given normal serum. Nor were differences detected in
subgroup analyses in patients who had had tracheotomies or other complications, or after
considering the sources of their infections (for example, from within families). Bingel was also
aware of the need to study large numbers of patients to reduce the effects of chance, and claimed
that his sample had been “sufficiently large to prove that no preference can be claimed for anti-
toxin serum” (Bingel 1918, p 331).   
Bingel’s challenging results provoked strong and often emotional reactions, which were reported
in the lay press. After all, an achievement crowned with a Nobel Prize was at stake, and thus the
prestige of German basic research. In general, the paper was simply dismissed. In response to
the sceptics (Bingel 1919), Bingel pointed out that he had never contested either the therapeutic
or the prophylactic value of Behring’s anti-toxin serum. He acknowledged a valid criticism that the
normal serum might have contained some anti-toxin, and admitted that such a possibility had not
occurred to him, as he assumed that what he had bought from industry labelled as “normal horse
serum” was what had been advertised. To address the criticism he commissioned analyses of
samples of the normal serum he had used. These did indeed reveal a very low concentration of
anti-toxin in some of the samples tested - roughly 1-3 international units per cubic centimetre.
Bingel deemed this to be so low that it could not have had any material effect when compared
with an anti-toxin concentration of 500 international units per cubic centimetre, leading to patients
receiving an average total dose of between 2000 and 8000 international units (Bingel 1919, p
739).
This argument prompted some of Bingel’s critics to admit that anti-toxin serum must contain other
unspecified therapeutic elements besides the anti-toxin, but it did not stop the defenders of anti-
toxin serum continuing to dismiss his provocative findings. As Bingel pointed out later (Bingel
1949, p 101), their views implied that 1-3 international units of serum were as effective as 500
units. He was also criticized for withholding from patients a proven effective therapy in order to
test a patho-physiological hypothesis. In response, he asserted that the final decision about the
therapeutic value in man of a drug stemming from animal experiments, however well justified
theoretically, remained with clinicians, and that it was also clinicians’ business, and not that of
serologists, whether such studies were to be regarded as consistent with medical ethics (Bingel
1919, p 740).
Bingel’s defence was clearly persuasive to some clinicians, however, and his request that his trial
be replicated was taken up by some other researchers. In 1933, for example, stimulated by
Bingel’s findings and their own observations of the effects of normal horse serum on the Schick
reaction, Hottinger and Toepfer (1933) reported four separate trials using alternation to generate
comparison groups, some using untreated controls. The largest of these trials alternated 400
patients to either anti-toxin serum or normal serum (Hottinger and Töpfer 1933). Like Bingel,
Hottinger and Toepfer were unable to detect any differential effects of the two sera, although they
stressed that their sample sizes had been inadequate to dismiss the possibility that important
differences might exist. They also reiterated that the responses of infected animals to sera might
well differ from the responses of diseased patients.  
In 1941, more than 25 years after publication of his first controlled trial, Bingel returned to
research on serum treatment of diphtheria (Bingel 1949). He explained for his readers that, after
the general disapproval of his 1918 paper, he had given in “to the decision of the majority of
physicians” and used anti-toxin serum for over twenty years, and he admitted that he had slept
better during those years. However, he also admitted that his decision to fall in line with the
majority of his colleagues had been made “without inner conviction”, and the issue continued to
nag him intellectually. He could not agree with those who held that scientific questions that had
not been addressed at the beginning of the serum therapy era could not be addressed later: “I am
of the opinion that it is never too late to uncover a scientific fact, even if notions that have held up
steadily over decades begin thereby to falter”. These considerations, and possibly the large
difference in price between anti-toxin serum and normal serum, prompted him to take up his
comparative studies again in 1941.
In midst of the Second World War, between 1 April 1941 and 30 September 1942, Bingel enrolled
nearly 1000 patients in a further comparison of anti-toxin serum and normal serum. The criteria for
inclusion were clearly defined, and he reported that allocation to the comparison groups had
again been by alternation, a method to which he now sought to give credibility by referring to Paul
Martini’s support of the approach (Martini 1932; Stoll 2004): “With this ‘alternating method’ I
believe I would achieve statistically irreproachable [einwandfrei ] results (see M a r t i n i)” (Bingel
1949, p 101). He again used ‘cover names’ (‘blue serum for anti-toxin serum and ‘red’ serum for
normal serum), which suggests that he repeated his earlier double blind methods (Bingel 1949, p
101), although nothing more specific was said about concealing the identity of the two sera being
compared. This time, the anti-toxin concentration was checked in the normal serum and found in a
concentration of only 1/100th of an international unit per cubic centimetre. As previously, Bingel’s
assistants and the head nurse, judging from their clinical “impressions”, differed over whether
they preferred the ‘blue’ or the ‘red’ serum. Between 1 October 1942 and 31 December 1943, he
ran a third controlled trial, again comprising 1000 cases. The Table summarizes the mortality
experiences in Bingel’s three controlled trials:
 Normal serum Anti-toxin serum
 deaths/N % deaths/N %
1st trial, 1913-1916 49/466 10.5 47/471 10.0
2nd trial, 1941-1942 45/458 10.0 57/514 11.1
3rd trial, 1942-1943 28/492 5.7 32/518 6.2
Bingel emphasises that “Solely the method of alternate treatment in a great number of patients
protects from false conclusions” (Bingel 1949, p 103), yet his two later trials do not appear to have
been as rigorously conducted as his first trial seems to have been. The differences in the sizes of
the comparison groups in the second and third trials suggest that the alternation scheme must
have been breached quite often, or alternatively that information on patients was lost in those
times of war. Furthermore, in his report of these trials he reveals that patients treated with normal
serum (and by implication, not those allocated anti-toxin serum) received some additional
therapies (for example, injections of their own blood). Not only would the comparisons have been
confounded because the groups would have differed in ways other than serum type, but
maintaining blinding would have presented problems.
Even so, Adolf Bingel’s writings reveal considerable methodological and epistemological
sophistication, and his application a century ago of a controlled, double blind, clinical trial
involving substantial numbers of patients was ahead of its time, not only methodologically, but
because his findings posed a serious challenge to the theory which had led to the development of
diphtheria antitoxin, and which had been assumed to explain its beneficial effects.
After Bingel had analysed the cases assembled in his three comparative trials, he gave his
answer to the question he had posed 30 years earlier. Anti-toxin was not the active agent in
serum therapy of human diphtheria; the sera acted non-specifically “as a stimulant activating the
defence forces [of the body]”. But Bingel’s cautious approach continued: at the end of his last
paper on the subject he advised his colleagues to continue using anti-toxin serum until his results
had been confirmed by others. But would anyone feel able to do a trial comparing antitoxin with
plain serum today?
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